Remarkable progress has been made in the development of biomarker-driven targeted
therapies for patients with multiple cancer types, including melanoma, breast and lung …

The approval of targeted therapies for metastatic colorectal cancer (mCRC) has led to
important improvements in patient outcomes. However, it is still necessary to increase …

Introduction: Metastatic colorectal cancer (CRC) remains a dilemma for cancer researchers
with an increasing incidence in the younger patient population. Until the last decade, limited …

Over the past decade there have been significant advances in the molecular
characterization of colorectal cancer (CRC) that are driving treatment decisions. Expanded …

In metastatic colorectal cancer (mCRC), an improved understanding of the underlying
pathology and molecular biology has successfully merged with advances in diagnostic …

Although significant progress has been made in colorectal cancer (CRC) treatment within
the last decade with the approval of multiple new agents, the prognosis for patients with …

Despite significant progress in management of metastatic colorectal cancer (mCRC)
pertaining to better screening procedures and amelioration of the therapeutic …

Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second
most common cause of cancer deaths. Initial clinical presentation as metastatic CRC …

Colorectal cancer is the second most common malignancy diagnosed in Canada. Despite
declining incidence and mortality rates in recent years, there is still a significant number of …

Over the past years, colorectal cancer (CRC) was subtyped according to its molecular and
genetic characteristics, allowing the development of therapeutic strategies, based on …